- Transition to a value-based care approach prioritizes quality outcomes over service volume, but calls for a dramatic overhaul of infrastructure, culture and operations.
- Shifting to value-based care means significant changes in mindset and practice among clinicians, while also disrupting traditional revenue models, creating initial financial risks.
- Leadership, data analytics, care coordination, and payer collaboration, are key to successful implementation.
- Adageis is structured to support providers during this transformation, with its unique offering of tools and solutions to simplify the necessary moves, including AI-driven analytics and patient-focused care solutions.
- The company’s platform is designed to help healthcare organizations optimize care delivery and improve reimbursement under value-based contracts.
The U.S. healthcare system is at a crossroads, shifting from fee-for-service models to value-based care. This transition prioritizes quality outcomes over service volume but requires a dramatic overhaul of infrastructure, culture and operations. Adageis, a forward-thinking healthcare technology company, is at the forefront of this shift, with its focus on revolutionizing patient care through innovative value-based care solutions.
The challenges of this shift to value-based care are significant. Financial uncertainty looms large, as providers accustomed to predictable revenues under fee-for-service models must now shoulder financial risk tied to patient outcomes. Many organizations also face gaps in their data systems, making it…
NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN